We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Markers for Early Detection of Heart Attack

By HospiMedica staff writers
Posted on 22 Nov 2000
A study of patients who presented to the emergency department with chest pain suggests that a blood test for monocyte-platelet aggregates can potentially detect heart attack in the critical early stages. More...
These results were presented at the Scientific Meeting of the American Heart Association in New Orleans by researchers from the University of Massachusetts Medical School (USA).

The study involved 211 consecutive patients admitted to the emergency department. Of the 61 who were actually having a heart attack, more than half were not yet apparent yet were found to have increased levels of circulating monocyte-platelet aggregates. This was an indication of the readiness of platelets to participate in clotting. The researchers concluded that monocyte-platelet aggregates are an early marker of heart attack.

The test for monocyte-platelet complex (MPC) was developed by scientists at the University of Florida Research Foundation (USA). The patented test has been exclusively licensed to CompuCyte Corp. (Cambridge, MA, USA), which is developing a test for use on its OnCyte Diagnostic System that gives results within 20 minutes. Currently available blood tests that detect heart-muscle damage often require hours of waiting for damage to occur and are not always conclusive.

"Since the majority of heart attacks have equivocal electrocardiographic changes and current blood tests may not be positive until six hours after the heart attack began, a very-early heart attack test is urgently needed,” noted Mark I. Furman, M.D., lead investigator in the study.



Related Links:
Compucyte

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Hypodermic Syringe
SurTract™ Safety Syringe
New
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Allevion Medical receives FDA Clearance for Vantage, introducing a fully disposable approach to minimally invasive spinal decompression (photo courtesy of Allevion Medical)

Single-Use System Enables Minimally Invasive Decompression for Lumbar Spinal Stenosis

Lumbar spinal stenosis is frequently driven by hypertrophic bone that narrows the canal and produces pain. Conventional decompression often relies on larger incisions and bulky retractors, adding time,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.